Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Lilly Seals Two New Drug Pacts
December 24, 2007
| A version of this story appeared in
Volume 85, Issue 52
Eli Lilly & Co. will lay out $87 million for access to BioMS Medical's lead multiple sclerosis compound, MBP8298. The drug is currently in two Phase II trials in secondary progressive MS and a Phase II study in relapsing-remitting MS. In addition to the upfront payment, BioMS could receive up to $410 million in milestone payments, as well as royalties on sales if the drug reaches the market. In a separate deal, Lilly will tap into protein optimization technology from privately held Ambrx to discover and develop treatments for metabolic diseases and central nervous system disorders.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X